Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2019-07-12 Board/Management Inform…
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 11, 2019, by Moleculin Biotech, Inc. The content focuses on the Compensation Committee's review and approval of executive compensation arrangements for the 2018/2019 and 2019/2020 compensation years, including stock option grants, bonuses, and changes to non-employee director compensation. The key section is Item 5.02, which relates to the departure, election, or appointment of directors or officers and compensatory arrangements. There is no financial statement or comprehensive financial report included; rather, it is an announcement of management and board compensation changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related compensation disclosures. The document length (9055 characters) and detailed content support this classification with high confidence.
2019-07-12 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 31, 2019, for Moleculin Biotech, Inc. The key content is an Item 7.01 Regulation FD Disclosure stating that the company will use the presentation set forth as Exhibit 99.1 in meetings with the investment community. The exhibit is described as an 'Investor Presentation dated May 2019.' The document explicitly states that the information is being furnished and not filed, and the main content is the investor presentation. The document length is 3652 characters, which is relatively short and primarily serves to announce and provide the investor presentation rather than being the presentation itself. According to the classification rules, this type of document is best classified as an Investor Presentation (IP) because it contains or references a detailed presentation for investors focusing on financials, strategy, and market position. The document is not a full financial report, earnings release, or regulatory filing beyond the 8-K format. Therefore, the classification is IP with high confidence.
2019-05-31 English
OWNERSHIP DOCUMENT
Director's Dealing
2019-05-24 English
OWNERSHIP DOCUMENT
Director's Dealing
2019-05-24 English
OWNERSHIP DOCUMENT
Director's Dealing
2019-05-24 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 22, 2019, for Moleculin Biotech, Inc. It reports the results of the 2018 Annual Meeting of Stockholders, including detailed voting results on multiple proposals such as election of directors, ratification of auditors, reverse stock split authorization, increase in authorized shares, and issuance of shares. The document primarily provides official voting results from the shareholder meeting. There is no detailed financial data or full report content, but rather the formal announcement of voting outcomes. According to the filing definitions, official results from shareholder votes at any general meeting correspond to Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7064 characters) and content confirm it is not a brief report publication announcement or a full annual report. Therefore, the correct classification is DVA with high confidence.
2019-05-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.